Business / Finance

RSS

Pacira first quarter total revenues increase to $7.8 million

Pacira Pharmaceuticals, Inc. today announced consolidated financial results for the quarter ended March 31, 2012 and reviewed recent accomplishments, including the commercial launch in the United States of EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain and the successful completion of an equity financing.

9 May 2012

ArcDia completes € 2.7 million funding round

ArcDia Ltd, the manufacturer of world's only multianalyte point-of-care diagnostic system for respiratory tract infections, completed today € 2.7 million funding round to expand its mariPOC diagnostics system.

9 May 2012

BioScrip first quarter revenue increases 19.0% to $24.8M

BioScrip, Inc. today announced 2012 first quarter financial results. First quarter revenue was $155.6 million and net loss was $2.7 million, or $0.05 per share. Consolidated Adjusted EBITDA for the first quarter was $8.4 million.

9 May 2012

Dental fraud of £73 million revealed as experts call for system overhaul

...

9 May 2012

Teva first quarter net revenues increase 25% to $5.1 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended March 31, 2012.

9 May 2012

SurModics second quarter revenue declines 8% to $12.2 million

SurModics, Inc., a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced results for its fiscal 2012 second quarter.

9 May 2012

Lannett third quarter net sales increase 19% to $30.7 million

Lannett Company, Inc. today reported financial results for the fiscal 2012 third quarter and nine months ended March 31, 2012.

9 May 2012

ACADIA first quarter net loss increases to $6.2 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2012.

9 May 2012

GenMark Diagnostics first quarter revenues increase to $2.2M

GenMark Diagnostics, Inc. today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

Medifast first quarter net revenue increases 20% to $88.9 million

Medifast, Inc.a leading United States manufacturer and provider of clinically proven, portion-controlled weight-loss products and programs, today reported financial results for the first quarter ended March 31, 2012.

9 May 2012

CardioNet first quarter revenue decreases 20.5% to $27.0 million

CardioNet, Inc., a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today reported results for the first quarter-ended March 31, 2012.

9 May 2012

Tornier first quarter sales increase to $74.5 million

Tornier N.V., a global medical device company focused on providing surgical solutions to orthopaedic extremity specialists, today reported its financial results for the first quarter of 2012 and updated its fiscal 2012 financial outlook.

9 May 2012

Bacterin International announces third national GPO contract with Novation

Bacterin International Holdings, Inc., a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, announces its third national GPO contract, a three-year agreement with Novation, a leading health care supply chain expert and contracting company.

8 May 2012

Bayer Yakuhin, Santen enter co-promotion agreement for EYLEA Injection in Japan

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced that Bayer's Japanese subsidiary, Bayer Yakuhin, Ltd., and Santen Pharmaceutical Co., Ltd. entered into a co-promotion agreement for EYLEA aflibercept) Injection in Japan.

From Santen Pharmaceutical Co., Ltd. 8 May 2012

Mindray first quarter net revenues increase 21.1% to $219.0 million

Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, announced today its selected unaudited financial results for the first quarter ended March 31, 2012.

From Mindray 8 May 2012

Hillenbrand second quarter net income decreases 17% to $27M

Hillenbrand revenue for the second quarter of 2012 grew 13% to $260 million compared to the same quarter last year.

8 May 2012

Genesis Biopharma terminates previously announced proposed public offering

Genesis Biopharma, Inc., a biotechnology company developing targeted cancer immunotherapies, announced today that it is terminating its previously announced proposed public offering pursuant to a preliminary prospectus supplement and an effective shelf registration statement on file with the Securities and Exchange Commission due to market conditions.

8 May 2012